Vashishtha Vipin M, Choudhury Panna, Kalra Ajay, Bose Anuradha, Thacker Naveen, Yewale Vijay N, Bansal C P, Mehta Pravin J
Correspondence to: Dr Vipin M Vashishtha, Convener, IAP Advisory Committee on Vaccines and Immunization Practices, Mangla Hospital and Research Center, Shakti Chowk, Bijnor, Uttar Pradesh 246 701, India.
Indian Pediatr. 2014 Oct;51(10):785-800. doi: 10.1007/s13312-014-0504-y.
There is a need to review/revise recommendations about existing vaccines in light of recent developments in the field of vaccinology.
Following an IAP ACVIP meeting on April 19 and 20, 2014, a draft of revised recommendations for the year 2014 and updates on certain vaccine formulations was prepared and circulated among the meeting participants to arrive at a consensus.
To review and revise recommendations for 2014 Immunization timetable for pediatricians in office practice and issue statements on certain new and existing vaccine formulations.
The major changes in the 2014 Immunization Timetable include two doses of MMR vaccine at 9 and 15 months of age, single dose recommendation for administration of live attenuated H2 strain hepatitis A vaccine, inclusion of two new situations in high-risk category of children in context with pre-exposure prophylaxis of rabies, creation of a new slot at 9-12 months of age for typhoid conjugate vaccine for primary immunization, and recommendation of two doses of human papilloma virus vaccines with a minimum interval of 6 months between doses for primary schedule of adolescent/preadolescent girls aged 9-14 years. There would not be any change to the committee's last year's (2013) recommendations on pertussis vaccination and administration schedule of monovalent human rotavirus vaccine. There is no need of providing additional doses of whole-cell pertussis vaccine to children who have earlier completed their primary schedule with acellular pertussis vaccine-containing products. A brief update on the new Indian Rotavirus vaccine, 116E is also provided. The committee has reviewed and offered its recommendations on the currently available pentavalent vaccine (DTwP+Hib+Hepatitis-B) combinations in Indian market. The comments and footnotes for several vaccines are also updated and revised.
鉴于疫苗学领域的最新进展,有必要根据这些进展对现有疫苗的建议进行审查/修订。
在2014年4月19日和20日举行的免疫接种咨询委员会(IAP ACVIP)会议之后,编写了2014年修订建议草案以及某些疫苗制剂的更新内容,并在会议参与者之间传阅以达成共识。
审查并修订2014年儿科医生门诊实践免疫接种时间表的建议,并就某些新的和现有的疫苗制剂发表声明。
2014年免疫接种时间表的主要变化包括:9个月和15个月龄时接种两剂麻疹-腮腺炎-风疹(MMR)疫苗;建议接种单剂量减毒活H2株甲型肝炎疫苗;在狂犬病暴露前预防方面,将两种新情况纳入高危儿童类别;在9至12个月龄时新增一个时间段用于伤寒结合疫苗的初次免疫;对于9至14岁的青春期/青春期前女孩的初次免疫程序,建议接种两剂人乳头瘤病毒疫苗,两剂之间的最短间隔为6个月。委员会去年(2013年)关于百日咳疫苗接种和单价人轮状病毒疫苗接种时间表的建议没有变化。对于之前已使用含无细胞百日咳疫苗产品完成初次免疫程序的儿童,无需额外接种全细胞百日咳疫苗。还简要介绍了新的印度轮状病毒疫苗116E。委员会已对印度市场上现有的五价疫苗(白百破+ Hib +乙肝)组合进行了审查并提出建议。还更新和修订了几种疫苗的注释和脚注。